NVE NVEC 深 滬
已收盤 12-12 16:00:00 美东时间
70.65
-2.660
-3.63%
華盛通- 最 高73.89
- 今 開73.74
- 成交量 4.49万股
- 最 低 69.92
- 昨 收 73.31
- 總市值 3.42亿
- 52周最高 84.50
- 市盈率 靜 22.70
- 換手率 0.93%
- 52周最低 48.5001
- 委 比 -99.00%
- 總股本 483.72万
- 歷史最高 105.00
- 量 比 0.84
- 振 幅 5.42%
- 歷史最低 1.27
- 每 手 1
- 風險率 6.39%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Shares of semiconductor stocks are trading higher after the Fed cut rates by 25 basis points.
Shares of semiconductor stocks are trading higher after the Fed cut rates by 25...
12-11 03:39
NVE Corporation Reports Decline in Quarterly Revenue
NVE Corporation ( ($NVEC) ) has released its Q2 earnings. Here is a breakdown o...
10-23 12:14
NVE declares $1.00 dividend
NVE (NASDAQ:NVEC) declares $1.00/share quarterly dividend, in line with previous. Forward yield 5.65% Payable Nov. 28; for shareholders of record Nov. 3; ex-div Nov. 3. See NVEC Dividend Scorecard, Yi...
10-23 04:47
Earnings Scheduled For October 22, 2025
Companies Reporting Before The Bell • Barclays (NYSE:BCS) is estimated to repor...
10-22 16:32
智光60MVA变频系统通过国家标准型式试验，再树行业新标杆
近日，广州智光电气股份有限公司全资子公司——广州智光电气技术有限公司(以下简称“智光电气技术”)自主研发的智能高压变频调速系统顺利通过国家电控配电设备质量检验检...
10-21 16:54
Alpha Cognition To Present New Clinical Insights On Cholinesterase Inhibitors And ZUNVEYL At The American Society Of Consultant Pharmacists Annual Meeting On October 23–25, 2025, And The Neuroscience Education Institute Annual Congress On November 6–9, 2025
Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition" or the "Company"), a commercial-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced it will present new
10-15 04:33
Reported Earlier, Alpha Cognition Prices $35M Oversubscribed Public Offering Of 5,600,000 Shares At $6.25 Each To Accelerate ZUNVEYL Commercialization
Offering was led by an initial investment from a premier healthcare-dedicated investor alongside multiple large existing shareholdersCompany's total cash position expected to be approximately $70 million following
10-01 13:49
兴证国际：维持康哲药业“买入”评级 独家产品及创新产品成为增长新驱动
兴证国际发布研报称，调整盈利预测，预计康哲药业（00867）2025-2027年归母净利润为16.61亿元、19.17亿元、22.72亿元，同比增长2.54%...
09-16 10:00
SLING TV UNVEILS "STREAM TEAM" LINEUP: 10 COLLEGE FOOTBALL PLAYERS SIGNED TO $4.99 NIL DEALS
Sling's new $4.99 Day Pass fuels a first-of-its-kind NIL movement proving streaming value beats streaming hype ENGLEWOOD, Colo., Sept. 12, 2025 /PRNewswire/ -- Sling TV, the most flexible li...
09-12 18:00
海通国际：维持康哲药业“优于大市”评级 目标价18.38港元
海通国际发布研报称，略微调整康哲药业（00867）2025-26E收入预期为83.3/93.0亿元，同比+11.5%/+11.6%；考虑公司创新转型的研发投入...
09-11 09:56
